UTIBRON

Drug Sunovion Pharmaceuticals Inc.
Total Payments
$4.7M
Transactions
59,811
Doctors
16,232
Companies
2

Payment Trends by Year

Year Amount Transactions Doctors
2020 $1,257 15 0
2019 $3,029 15 0
2018 $544,752 5,582 2,833
2017 $4.1M 54,199 15,134

Payments by Nature

Nature of Payment Amount Transactions Share
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $2.8M 1,223 60.6%
Food and Beverage $796,956 47,899 17.0%
Travel and Lodging $651,655 3,363 13.9%
Unspecified $358,102 123 7.6%
Consulting Fee $24,673 7 0.5%
Education $19,638 7,196 0.4%

Payments by Type

General
$4.3M
59,688 transactions
Research
$358,102
123 transactions

Research Studies & Clinical Trials

Study Name Sponsor Amount Doctors
A MULTI CENTER RANDOMIZED DOUBLE BLIND DOUBLE DUMMY 2 PERIOD CROSS OVER AND ACTIVE CONTROLLED STUDY TO ASSESS THE EFFICACY SAFETY AND TOLERABILITY OF INDACATEROL AND OR GLYCOPYRRONIUM BROMIDE IN PATIENTS WITH MODERATE TO SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE Novartis Pharmaceuticals Corporation $346,822 0
A 12 WEEK TREATMENT MULTI CENTER RANDOMIZED DOUBLE BLIND PARALLEL GROUP PLACEBO AND ACTIVE CONTROLLED STUDY TO ASSESS THE EFFICACY SAFETY AND TOLERABILITY OF QVA149 INDACATEROL MALEATE AND OR GLYCOPYRRONIUM BROMIDE IN COPD PATIENTS WITH MODERATE TO SEVERE AIRFLOW LIMITATION Novartis Pharmaceuticals Corporation $6,993 0
A MULTI CENTER RANDOMIZED DOUBLE BLIND DOUBLE DUMMY 2 PERIOD CROSS OVER AND ACTIVE CONTROLLED STUDY TO ASSESS THE EFFICACY SAFETY AND TOLERABILITY OF INDACATEROL AND OR GLYCOPYRRONIUM BROMIDE IN PATIENTS WITH MODERATE TO SEVERE CHRONIC OBSTRUCTIVE PULMONA Novartis Pharmaceuticals Corporation $4,286 0

Top Doctors Receiving Payments for UTIBRON — Page 2

Doctor Specialty Location Total Records
, M.D Pulmonary Disease Georgetown, KY $29,989 66
, M.D Critical Care Medicine Ypsilanti, MI $29,651 64
, M.D Critical Care Medicine South Boston, VA $28,691 80
, MD Pulmonary Disease Snellville, GA $28,486 80
, MD Geriatric Medicine Centerville, OH $27,126 66
, M.D Specialist Tyler, TX $26,935 72
, M.D Internal Medicine Livonia, MI $26,909 31
, M.D Pulmonary Disease Corpus Christi, TX $26,547 33
, M.D Internal Medicine Albany, NY $25,982 53
, MD Pulmonary Disease Saint Charles, MO $25,781 61
, MD Pulmonary Disease Oakton, VA $25,713 59
, MD Critical Care Medicine Pittsburgh, PA $25,234 46
, M.D Pulmonary Disease Washington, MO $24,901 34
, M.D Allergy Columbia, MO $24,618 57
, MD Internal Medicine Kenosha, WI $22,854 66
, DO Family Medicine Sterling Heights, MI $22,504 82
, D.O Critical Care Medicine Port Saint Lucie, FL $22,154 38
, MD Pulmonary Disease Little Rock, AR $20,402 39
, M.D Critical Care Medicine Rocky Mount, NC $19,381 55
, DO Critical Care Medicine Scottsdale, AZ $19,186 38
, MD Critical Care Medicine Glastonbury, CT $19,091 41
, M.D Pulmonary Disease Shreveport, LA $18,463 51
, M.D Pulmonary Disease Nashville, TN $17,843 50
, MD Pulmonary Disease Corning, NY $17,835 45
, MD Pulmonary Disease Akron, OH $17,084 41
«1234…650»

Manufacturing Companies

Product Information

  • Type Drug
  • Total Payments $4.7M
  • Total Doctors 16,232
  • Transactions 59,811

About UTIBRON

UTIBRON is a drug associated with $4.7M in payments to 16,232 healthcare providers, recorded across 59,811 transactions in the CMS Open Payments database. The primary manufacturer is Sunovion Pharmaceuticals Inc..

Payment data is available from 2017 to 2020. In 2020, $1,257 was paid across 15 transactions to 0 doctors.

The most common payment nature for UTIBRON is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($2.8M, 60.6% of total).

UTIBRON is associated with 3 research studies, including "A MULTI CENTER RANDOMIZED DOUBLE BLIND DOUBLE DUMMY 2 PERIOD CROSS OVER AND ACTIVE CONTROLLED STUDY TO ASSESS THE EFFICACY SAFETY AND TOLERABILITY OF INDACATEROL AND OR GLYCOPYRRONIUM BROMIDE IN PATIENTS WITH MODERATE TO SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE" ($346,822).